About

Shield Therapeutics PLC is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals that address patients’ unmet medical needs, with an initial focus on iron deficiency with or without anaemia (ID/IDA) with its approved product Feraccru®.

At a glance

Shield is a de-risked commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs.

Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of Iron Deficiency with or without anaemia in adult patients which has exclusive IP rights until the mid-2030’s.

CEO & Founder

Carl Sterritt

Shield has been transforming itself from a wholly development-focused and private company into a listed and increasingly commercially-focused, customer-facing organisation. We are now well positioned to become a fast growing, independent, international specialty pharmaceutical company and, due to the strength of our products and team, and with great thanks to all of our supportive shareholders, I look forward to the future with great excitement.

What sets us apart

  • Lead product Feraccru®

    Currently approved in the European Union and Switzerland, Feraccru® offers a number of important advantages compared to current standards of care for Iron Deficiency with or without anaemia. Feraccru® is commercially available in the European Union and actively marketed by Norgine B.V. and AOP with more patients than ever being treated.

  • Large market opportunities with unmet needs

    In Europe it is estimated that there are more than 40 million people with Iron Deficiency with or without anaemia, representing a significant commercial opportunity for Feraccru®.

  • Experienced management team with extensive expertise

    The skilled senior management team and board of directors provide strong leadership for the Company’s future growth.

  • Strong intellectual property protection

    The Group’s assets are supported by a suite of robust intellectual property rights including key patents in major markets. The Group’s marketed product, Feraccru®, for the treatment of Iron Deficiency with or without anaemia in adults and has exclusive IP rights until the mid-2030’s.

London, UK

16 Upper Woburn Place
Euston
London, WC1H 0AF

t+44 (0) 207 186 8500

einfo@shieldtx.com

Newcastle, UK

Northern Design Centre
Baltic Business Quarter
Gateshead Quays, NE8 3DF

t+44 (0) 191 511 8500

einfo@shieldtx.com

Wollerau, Switzerland

Sihleggstrasse 23,
8832 Wollerau
Switzerland

t+41 (0) 435 080 781

einfo@shieldtx.com

Munich, Germany

Oranienburger Str. 3
c/o Lambsdorff Rechtsanwälte PartGmbB
10178 Berlin
Germany

t+44 (0) 207 186 8500

einfo@shieldtx.com